Presentation on theme: "IP Valuation Dr. Rahul Verma, Assistant Vice President,"— Presentation transcript:
1IP Valuation Dr. Rahul Verma, Assistant Vice President, Intellectual Property and Legal Support ServicesApril 2010
2Presentation Plan IP Valuation Overview IP Valuation Approaches Case StudyAppendix2
3Presentation Plan IP Valuation Overview IP Valuation Approaches Case StudyAppendix3
4Biotechnology Industry in India (1/2) The Indian biotechnology industry is estimated to be more than USD 2.6 billion. This accounts for about 3% of the global biotechnology sector.The revenues for the industry have grown from Rs. 2,345 crores in 2002 – 03 to Rs. 12,137 crores in 2008 – 09.It can be divided into the following five segments: BioPharma, BioServices, BioAgriculture, BioIndustrial and BioInformatics.BioPharmaBioServicesBioAgricultureBioIndustrialBioInformaticsIncludes medicines prepared by recombinant DNA technologyRevenue – Rs. 7,883 crores in 2008 – 09Includes clinical research, contract research organizations and custom manufacturingRevenue – Rs. 2,062 crores in 2008 – 09Includes manufacturing commodities for human and livestock consumptionRevenue – Rs. 1,494 crores in 2008 – 09Includes enzyme manufacturingRevenue – Rs. 478 crores in 2008 – 09Includes computer software tools for data management, database creation, data mining and data warehousingRevenue – Rs. 220 crores in 2008 – 09Sources: Link1, Link2, Link3
5Biotechnology Industry in India (2/2) Apart from the above mentioned five sectors of the Indian biotechnology industry, there are other emerging sectors like Biosimilars, Nanotechnology and Stem Cell Research.Biosimilars – This includes biotechnology-based drugs similar to biologic drugs that enter the market after the innovator drug goes off patent. The biosimilars market in India is expected to reach USD 2 billion in 2014.Stem Cell Research – This market is expected reach USD 540 million in 2010.
7The Chindia Story China India In 2009 – Despite global economic downturn, the Chinese Patent Office (SIPO) received a total of 976,686 patent applications, with a growth rate of 18% over the previous year.During 1999 – 2009: About five million patent applications were filedIf the current growth rates remain the same, China will surpass the US in 2012 with respect to the invention patent application filingsChina20-21% annual increase in patent filingIP awareness is spreading among Indian companiesIPR reforms reflect seriousness of the governmentIndia7
8Patenting trends in India The patent filing in India has been on the rise in the last few years. The Figure below illustrates the increase in the filing activity in various technical fields of the life science domain over the last five years.
9Two Perspectives of Technology Licensing in Indian Context India ranks 30th out of 134 countries on Prevalence of Foreign Technology LicensingTwo Perspectives of Technology Licensing in Indian ContextMNCs partnering with Indian companies with innovationsMNCs entering the Indian market
10Foreign Technology Licensing in India MNCs partnering with Indian companies with innovationsMNCs entering the Indian marketImtech licensed a new drug molecule to Nostrum Pharmaceutical for USD 3 million in 2009.Imtech, a CSIR laboratory licensed a clot-busting therapeutic protein to US-based Nostrum Pharmaceutical for USD 20 million in 2006Shasun, Indian drug manufacturing firm, sign non-exclusive license with Merck.Indoco Remedies Ltd., a Mumbai-based generic company, announced a technology licensing agreement to produce generics with Watson Pharmaceuticals, Inc. Watson will file an ANDA for US FDA approval.Pfizer entered into licensing agreements with India’s Strides Arcolab, Aurobindo and Claris LifeSciences for supply of generic products and injectiblesEvolving Indian market and customer feel the need for advanced and world-class products and servicesAutomatic permission for foreign technology agreements in a few industriesCSIR has signed a MOU with San people of South Africa for commercialization of Hoodia, as a blockbuster anti-obesity drug.Eisai, a Japanese pharma major to set up manufacturing and research base in India.
11Presentation Plan IP Valuation Overview IP Valuation Approaches Case StudyAppendix11
12Growing Importance of IP Valuation Increased focus of industry and markets on knowledge-based marketSince intangible assets form the backbone of any company, their valuation is important from the market perspective.With industry- and production-based economies worldwide giving way to a knowledge-based economy, intangible assets are gaining importance in the market value of a company.This is evident from the graph which shows that the contribution of intangible assets to the components of the Standard & Poor's 500 market value has increased from 17% in 1975 to about 80% in 2005.IP is one of the most important intangible assets, with trademarks, copyrights, trade secrets, and patents becoming vital money-making tools for a company.There is an increasing need for shifting research focus from valuing tangible assets to valuing intangible assets.Source – Ned Davis Research
13Monetizing IP – Patents Patent Monetizing IdeasAggressive Marketing of ProductsPatents as a Business ConceptPortfolio of Stocks with Strong Patent PortfolioAdobe markets its key product, Adobe Reader 7.0, with 51 utility US patents, 4 US design patents, and patent pending legal noticesA 2002 study by the Equipment Leasing and Finance Foundation listed the market value of patent-based licenses at USD 1 trillion in the USOcean Tomo 300™ Patent Index, the first equity index based on the value of corporate IP of 300 diversified companies, was launched in 2006; it is published by AmexIt is very important for a startup to attract consumers to its products and get VCs to fund your venture. As the awareness of VCs and consumers grows towards the knowledge-driven market, attention is also paid to the patents that accompany a product. Aggressive marketing of products refers to companies using the patent pending status of their inventions to reap rich benefits from VCs and consumers alike, for example Adobe.After gaining a small foothold in the market, the next step is to establish oneself—this is where patents are used as a business concept. You can monetize your portfolio of patents by licensing or selling the technology to companies. You can also gain more market share by issuing damaging lawsuits on competitors. In fact there is a concept of “patent trolls” that has developed in the market over past decade. They identify worthwhile and good patents from individual investors or small time companies and then make money by either licensing them out , or selling them or even by issuing lawsuits on companies.For established firms in the market, besides the above two points it is also worthwhile to note the emergence of indices and stocks being built based on patent portfolio of companies. Ocean Tomo 300In addition, based on the back-calculations and findings published by the American Stock Exchange for evaluating this index from 1996 to 2006, the index would have outperformed S&P 500 by average of 500 basis points per annum.
14Context for IP Valuations Small and Medium Enterprises in Hi-Tech DomainsPharmaceutical CompaniesElectronics and Computer Hardware FirmsLicensing DealsSale of IPIP Brokerage Firms and Medium-Sized EnterprisesM&A DealsConsulting FirmsInvestment BanksPrivate Equity FundsInfringement LawsuitsInfringement Support Law FirmsPlaintiff/DefendantFinancing/ SecuritizationBanksPrivate Equity FundsVCsTax/Financial ReportingAny
15Patent Valuation and Product Valuation Valuation methods, particularly early in the life of a patentable ideaLifecycle of a patentFuture and uncertainties of the technology, e.g., new and ongoing research, lifecycle/term of a patent, and income attributable to a patentLegal issues on jurisdictionsValuation methods, before launching a product in the marketCost of OEMsFuture and uncertainties of the product market, e.g., growth trends, lifecycle of a product and competing products available in the marketThe whole world is a potential marketPractical valuation methods are desirable for both patents and products. For patents it is important that valuation be done early in the life of a patent so that optimal decision can be reached regarding the course of action. For products, valuation at the launch of the product is used to determine the market entry price that will vary based on market parameters.Patent valuation is usually performed by various techniques based on lifecycle of patent. For example, a patent pending idea will be valued using a different approach than a granted patent that has recently been used in the industry or a granted patent based on which lots of products are already in the market. This will also be covered in detail later in the presentation. Product valuation on the other hand is usually performed using OEM cost.Valuation of patent involves making judgments about the future and uncertainties of the technology, e.g., new and ongoing research, lifecycle/term of patent, and income attributable to patent. Valuation of products involves making judgments about the future and uncertainties of the market of the product, e.g., growth trends, lifecycle/term of product and competing products available in the marketLegal issues such as the amount of coverage and the jurisdiction in which coverage is offered by the patent are important factors during patent valuation. In case of product valuation, essentially the entire world is your market, but you will have to consider if you have freedom to operate a product in a particular jurisdiction.Patent and product valuation go hand in hand. To estimate the value of a patent or product, knowledge about the related product or patent and the associated market/legal boundaries is helpful.
16Factors for IP Valuations of Biotechnology Invention Novelty of the technologyCompetitive technologies/products in the domainBenefits of the technology over the competing technologiesIP Landscape in the domainRegulatory requirementsEfficacy of the productTarget MarketNovelty – Highlight and quantify the novel feature of the technologyCompetitive technology – Assess the technology landscape to identify the competitors and their hold on the target marketBenefits of technology over the competing technologies – differentiate the current technology from the competitive technologies highlighting the shortcomings of the competitors that are overcome by the current technologyIP landscape – to identify the emerging technologies in the domainRegulatory requirements – identify the cost and the time required for regulatory approvalsEfficacy of the product – highlight the working efficiency of the product based on the technologyTarget market – identify the market size as well as geographic region that can be the most appropriate market for the productMarket acceptance – This is an issue for most recent biotech inventions like GM (genetically modified) crops and stem cell therapy. Due to hesitation by the customers in accepting the new technology, the market penetration reduces.Cost of the product – In comparison to substitute products in the domain. This will also effect the market penetration.Marketing Strategy – This will change based on the technology/product and the target costumers. Eg: In case of a new drug for cancer therapy, the doctors will be the target customers. So marketing will be through medical representatives or conferences and symposiums. This additional cost will have to be taken into account when calculating the licensing amount.BiogenericsOriginal drug going off patent – This will influence the launch time/year for the productEfficacy – to establish that the biogeneric should be able to replace the innovator drug as well as other chemical based generic drugsMajor players – This will influence the market penetration of the biogeneric. Higher the number of competitors lower the market penetrationCost - This will also affect the market penetration. Higher the cost lower the percentage of market that can be captured.Clinical TrialsNovelty – Process of conducting the clinical trials. As the actual process is very well known, it is very important to highlight the innovation/novelty of the current process.Quantifying the benefit – As it is a process patent, the benefits (ease of conducting the trials, less time consuming, more accurate results, better interpretation of results etc) will have to be quantified in monetary terms.Target market – The same process for conducting clinical trials might not work well for all technologies. Thus, it is important to identify the exact market.Market acceptanceCost of the productMarketing Strategy
17Process Flow in a Typical IP Valuation UnderstandingIPAssessing IPStrengthAssessing IP-Centric FactorsIdentifying Market for IPBuilding Valuation ModelUnderstand how is the IP different from other existing IP in the marketWhat are the competing companies and technologiesWhat does the IP uniquely add to the marketWhat factors of market demand does it satisfyHow powerful is the IP in terms of the existing IPWill it sustain an invalidation attempt by competitorsHow does the IP fare in comparison with competing technologies, in terms of major advancement or minor adjustmentHow broadly does the IP claimIn which jurisdiction is the IP applicableWhat is the remaining life of the IPAre there any risks associated with government rules with the IPWhat is the market for the technical domain in the specific jurisdictionWhat is the growth trend of the marketWhat is the lifecycle of the IPWhat is the discount rate for the DCF modelingHow sensitive is the value on the estimations used in the model17
18Approaches for IP Valuation Valuation ApproachesComparableApproachCostApproachIncomeApproachValue EstimateMultiples or prices of market transactions involving the sale of comparable IPValue EstimateReproduction/ replacement cost adjusted for depreciation and obsolescenceValue EstimatePresent value of earnings attributable to the IP or costs avoided as a result of owning the IPIt is very important for a startup to attract consumers to its products and get VCs to fund your venture. As the awareness of VCs and consumers grows towards the knowledge-driven market, attention is also paid to the patents that accompany a product. Aggressive marketing of products refers to companies using the patent pending status of their inventions to reap rich benefits from VCs and consumers alike, for example Adobe.After gaining a small foothold in the market, the next step is to establish oneself—this is where patents are used as a business concept. You can monetize your portfolio of patents by licensing or selling the technology to companies. You can also gain more market share by issuing damaging lawsuits on competitors. In fact there is a concept of “patent trolls” that has developed in the market over past decade. They identify worthwhile and good patents from individual investors or small time companies and then make money by either licensing them out , or selling them or even by issuing lawsuits on companies.For established firms in the market, besides the above two points it is also worthwhile to note the emergence of indices and stocks being built based on patent portfolio of companies. Ocean Tomo 300In addition, based on the back-calculations and findings published by the American Stock Exchange for evaluating this index from 1996 to 2006, the index would have outperformed S&P 500 by average of 500 basis points per annum.18
19Approach usage rationale Comparables ApproachApproach usage rationaleDisadvantageComparing the IP to comparable assets recently exchanged under similar circumstancesFinding a comparable asset in same technology domain as the IP to be valued can be difficultComparing two different IPs, even the ones in the same domain can be difficultAdvantageProcessComparatively simpler method of valuationEstablish IP comparability: type of asset, industry relevance, geographical constraints, timeframe, financial characteristics of underlying operationsLocating similar licensing dealsThis method is very easy to use and estimates the value of IP based on past occurrences
20Approach usage rationale Cost ApproachApproach usage rationaleDisadvantageDetermine the value of patent by aggregating the costs involved in its developmentDetermine ‘Reproduction Cost’ to reproduce the same assetCost based approach provides a benchmark for management to control cost of development and not a fair value of the IPThe data is not publicly availableAdvantageProcessIt is a simple methodIt is easy to useCollect and analyze IP R&D cost client dataReview comparable cost data of similar IPsIdentify direct cost and multiples for allocation of indirect costPrepare a cost sheet for the IP R&D projectIf the cost approach is to be used at the product manufacturing stage (IP management), should not the production costs also be included. R&D costs can be wrong indicator as prototype building is always expensive and may give exaggerated value of the IP even if this approach is used at an intermediate stage of IP Protection and IP Management.This method is useful in identifying the floor value of IP20
21Approach usage rationale Income ApproachApproach usage rationaleDisadvantageEstablish ability of patent to generate economic benefits over the property’s useful lifeWhen discount rate for the IP can be known with certainty but not cash flowsDiscounted Cash Flow (DCF) is a static modelIt only captures the expected cash flows and does not account for uncertaintyAdvantageProcessGives a very objective value of the IP in relation to the marketProportion of the revenue attributable to the subject IPEstimating size and growth rate of relevant industryEstimate revenue, risk and growth associated with the IP proportion of the revenue attributable to the subject IPApplication of DCF, Monte Carlo and option pricing techniquesThis method is useful in identifying the intrinsic value of IP21
22Presentation Plan IP Valuation Overview IP Valuation Approaches Case StudyAppendix22
23What methodology will you follow to identify the price of the patent? Case Study*: How do we actually value a patent?What is patented?Objective and NeedA biosimilar drug molecule for treatment of autoimmune diseases.You need to present the patented idea to a pharmaceutical company to sell the patent.They are already convinced that there is a market that can be tapped.You need to identify the target market and what value should you go to the negotiation table with.What methodology will you follow to identify the price of the patent?Assess the strength of IP and the competing IP in the spaceIdentify market targeted by the IP based on IP centric parametersIdentify licensing amountThe patent also claims the method of production and purification of the molecule. Further, the patent protection of the innovator drug will be over in the near future.*: Indicative numbers have been used in this case study
24Market Parameters for Valuation (1/2) The market size was calculated to be more than USD 9 bilion in The calculation is based on the market for the original drug of which biosimilar has been invented.The market figures were confirmed by surveys with Subject Matter Experts or secondary sources in the biosimilar market and forecast status of market.The market penetration and price discount was calculated on the basis of a report by CAGW on target market penetration and price discount for biosimilar.Identify the target market and growth rate of the market for the biosimilarMarket penetration & price discount – the biosimilar can be classified as low range, mid-range or high range.
25Market Parameters for Valuation (2/2) Based on IP analysis, and competitive intelligence you can determine if your new drug is a high-range, medium-range or low-range drug.Assuming it to be a medium-range biosimilar, you can expect a market penetration of 3% in the year of launch and 40% after 6 years.Again for a medium-range biosimilar the price of the product will also be reduced based on price discountThe market share for intermediate years was calculated on the basis of S-curve.The cost of conducting clinical trials for FDA approval will require approximately USD 25 million over the next 4 years.The average royalty rates on sales in the pharmaceutical sector have been found to be 6%.The discount rate has been assumed based on the industry standard for pharmaceutical sector. This has been confirmed by the risk assessment matrix or the SWOT analysis of the technology.FDA approvalRoyalty rate - les Nouvelles Dec 2002; Royalty Source Transaction Analysis; Dan McGavock – IPCDiscount rate
26IP Parameters for Valuation IP Landscape analysis was conducted to identify relevant IP in the domain. Intensive IP analysis, such as broadness of claims, details of office actions can help in identifying the share of the market that can be attributed to current technology.Active companies in the technology domain were identified as they can influence the market captured by the current biosimilar.Both these parameters have been factored in the risk assessment matrix while calculating the discount rate that can be offered.
27Strength of the patents Risk Assessment/SWOT analysisParameterLevel 1Level 2Level 3Level 4Level 5Demand LevelNo existing demandSpurious demandLow demandMedium demandHigh demandCustomer SegmentUnidentifiableIdentified and growing slowlyIdentified and small sizeIdentified and moderate sizeIdentified and huge sizeTechnologyNew and not testedNew and tested but with marginal resultsNew but positive resultsExisting and growing rapidlyExisting and well established but not growing rapidlyProductNew and not tested in the marketNew but positive feelingExistingOld product, re-launchSubstitute ProductsNumerous and very goodNumber fairly highFew and very goodFew but with old technologyNo substitutesStrength of the patentsLow; Clustered domain of patentsModerate; Numerous other patentsModerate; Few patents in the domainHigh; Few patents in the domainVery High; Are key patents
28Life Cycle AnalysisIt is assumed that biosimilars will start gaining market share only in Further, 3% market penetration will be achieved in 2013 and market penetrations of 30% will be achieved by 2018.
29(Amounts in USD million) DCF Valuation Model (1/3)(Amounts in USD million)ValuesCurrentForecasted201020112012201320142015Overall Market Size95161037211300Market Penetration0%3%12%22%Price Discount %20%29%34%Target market2288831668Market Share of invention91353667Market Share10%Royalty Earnings5.521.249.2Licensing/Milestone payments2.557.510Royalty Rate6%Discount Rate25%Present Value6.78.9188.8.131.52.7Licensing/Milestone payments is the approximate amount required for conducting clinical trials.29
30(Amounts in USD million) DCF Valuation Model (2/3)(Amounts in USD million)Forecasted2016201720182019Terminal ValueOverall Market Size1153211760120021223924,475Market Penetration31%36%40%43%Price Discount %37%39%41%Target market22262612287930736146Market Share of invention8901045115212292458Market ShareRoyalty Earnings75.093.5107.0117.0233.3Licensing/Milestone paymentsRoyalty RateDiscount RatePresent Value22.5 23.522.320.333.830
31Post Tax Net Present Value DCF Valuation Model (3/3)Pre-Tax Net Present Value117.84R&D Success Probability (FDA approval Probability)60%Post Tax Net Present ValueUSD 52 millionBio-equivalent molecules are a sort of “generic“ version of the original molecule that needs to display bio-equivalence, thus the probability of R&D success will be higher or similar to that of a generic molecule.Two taxation scenarios:30% on all income – standard30% on 20% of the royalty income - R&D/ Biotech business enjoys tax holidays on several fronts
32Presentation Plan IP Valuation Overview IP Valuation Approaches Case StudyAppendix32
33Structure of IP Valuation Curriculum Highlights various parameters on which IP valuation can be dependent, such as jurisdiction for legal protection, duration of protection, market attributable to an IP, and risk factors involvedHelp in understanding the various parameters for modeling a valuation solution, such as forecasting revenue streams, royalty rate estimations, accounting for risk premiums in discount rate calculations, sensitivity analysis, real-option pricing, and Monte Carlo SimulationsIntellectual Property ProgramsFinancial ProgramsIP + FinanceIntersection of Intellectual Property and Finance ProgramsValuation of IP requires knowledge of both IP and financeKnowledge of IP helps in determining the parameters that affect revenue streams, volatility, and other risk factorsImportant to understand IP factors as they play a crucial role in determining financial parameters that affect valuationKnowledge of finance necessary to identify the number associated with the IP factorsCombination of IP and finance also helps in understanding how real option pricing and Monte Carlo Simulations can be used to assess the impact of estimations on valuationTake an instance of patent valuation and comment on the parameters…Lets take patent valuation as an example, it is important to know what is the life of the patent (that helps in identifying till which year revenue streams need to be accounted for), jurisdiction in which the patent/patent family is effective (this helps in estimating the market size), the breadth of claims (that helps in identifying how much market can it capture), technical analysis of the patent with respect to the other IP in the space (to estimate the market needs that the IP is trying to address)…All these and many more IP specific parameters need to be incorporated in a financial model.
34Existing CurriculumsThe National Law University, Jodhpur, is the first university in India to offer Masters Degree, and Honors and Distance Education Programs in IPR. IPR Honors program has eight papers, one of which is IP Valuation.The PSB Academy, an institute in Singapore, offers a one-day lecture-cum-enhanced learning through case studies training program–Intellectual Property Management for Enterprise Managers. Their training on IP Valuation comprises purpose of intangible asset valuation, commonly-used IP valuation approaches, and IP asset valuation criteria.Bournemouth University, Center for Intellectual Property Policy & Management, specializes in copyright, industrial design, patents, trade marks, law & policy, IP exploitation, and legal education. It offers Customized IPR Short Courses—a half-day, a one-day and a two-day course, including IP licensing and IP valuation.As such a few financial curriculums in law and business school have some courses, case study sessions and seminars on IP valuations. These are just a few of those. Stern Business School has IP Valuation as a part of curriculum.However, there is a growing need to develop the art of IP valuation into a science and teach it as a course in technical institutes since most of the parameters, calculation steps have to be based on technical details of the IP.Telestrat Education is a worldwide leader in continuing education seminars. It provides a half-day course on IP Valuation, which includes valuation basics, valuation methods, discount rate, and cost of capital knowledge.
35Research Topics and References Estimating growth rate of revenue streams from an IP by using SWOT analysis based on IP-specific risk parametersAccounting for IP parameters, such as FDA approvals in the case of a biotech IP, as risk premiumsEstimation of royalty rates for IP in various technical domainsReal-options and binomial approach—when treating patents as an asset with an option of creating products based on the patents now or laterResearch TopicsStrategies for Investing in Intellectual Property by David S. RuderEssentials of Licensing Intellectual Property by Alexander I. Poltorak, Paul J. LernerIntellectual Property Assets in Mergers and Acquisitions by Melvin SeminskyReferencesLots of research material and books available on Valuation of IP. These are just a few of those.